UNASSIGNED:在高级别神经胶质瘤(HGG)中使用(18)F-氟-乙基-酪氨酸(18F-FET)的选择性摄取,以通过正电子发射断层扫描(PET)评估肿瘤的代谢活性。我们的目标是研究它对目标体积定义的价值,作为一个预言家,以及与全血转录组液体活检(WBTlbx)的关联,我们最近报道了在复发性HGG(rHGG)中反映肿瘤特征和对粒子照射反应的可行性。
UNASSIGNED:评估了n=43例原发性胶质母细胞瘤(pGBM)患者和n=33例rHGG患者的18F-FET-PET数据。pGBM患者接受光子照射和连续质子/碳增强,rHGG患者接受碳再照射(CIR)治疗。WBT(IlluminaHumanHT-12表达BeadChips)lbx可用于来自rHGG队列的n=9名患者。PET等高线(40%-70%SUVmax,使用符合性指数(CI)(pGBM,n=16;rHGG,n=27)。在基因表达水平和推断的途径活性评分(PROGENy)以及转录组估计的细胞分数(CIBERSORT,xCell)。
未经批准:在pGBM中,PET获得放疗前的中位SUVmax较高(4.1,范围(R)1.5-7.8;n=20)。放疗期间(3.3,R1.5-5.7,n=23;p=0.03)和未切除的(4.7,R2.9-7.9;n=11)与切除的肿瘤(3.3,R1.5-7.8,n=32;p=0.01)。在rHGG中,在IV级肿瘤中观察到更高的SUVmax值的趋势(p=0.13).pGBM(n=16)的MRIvol中位数为32.34(R8.75-108.77)cm3,rHGG患者(n=27)的MRIvol中位数为20.77(R0.63-128.44)cm3。最高的medianCI为40%(pGBM,0.31)和50%(rHGG,0.43,所有肿瘤)等剂量,在III级(IV)rHGG肿瘤中具有70%(40%)等剂量(medianCI,0.38和0.49)。高SUVmax与pGBM(>3.3,p=0.001,OR6.0[2.1-17.4])和rHGG(>2.8,p=0.02,OR4.1[1.2-13.9])的较短生存期相关。SUVmax显示与推断的单核细胞分数相关,缺氧,和TGFβ途径活性以及与WBTlbx免疫检查点基因表达的联系。
UNASSIGNED:18F-FET-PET成像对粒子放射治疗的大体肿瘤体积(GTV)定义的益处值得进一步评估。SUVmax可能有助于HGG患者粒子放疗的预后分层,突出了rHGG的异质性,并且与外周血全血转录组的不良特征呈正相关。
UNASSIGNED: Selective uptake of (18)F-fluoro-ethyl-tyrosine (18F-FET) is used in high-grade glioma (HGG) to assess tumor metabolic activity via positron emission tomography (PET). We aim to investigate its value for target volume definition, as a prognosticator, and associations with whole-blood transcriptome liquid biopsy (WBT lbx) for which we recently reported feasibility to mirror tumor characteristics and response to particle irradiation in recurrent HGG (rHGG).
UNASSIGNED: 18F-FET-PET data from n = 43 patients with primary glioblastoma (pGBM) and n = 33 patients with rHGG were assessed. pGBM patients were irradiated with photons and sequential proton/carbon boost, and rHGG patients were treated with carbon re-irradiation (CIR). WBT (Illumina HumanHT-12 Expression BeadChips) lbx was available for n = 9 patients from the rHGG cohort. PET isocontours (40%-70% SUVmax, 10% steps) and MRI-based treatment volumes (MRIvol) were compared using the conformity index (CI) (pGBM, n = 16; rHGG, n = 27). Associations with WBT lbx data were tested on gene expression level and inferred pathways activity scores (PROGENy) and from transcriptome estimated cell fractions (CIBERSORT, xCell).
UNASSIGNED: In pGBM, median SUVmax was higher in PET acquired pre-radiotherapy (4.1, range (R) 1.5-7.8; n = 20) vs. during radiotherapy (3.3, R 1.5-5.7, n = 23; p = 0.03) and in non-resected (4.7, R 2.9-7.9; n = 11) vs. resected tumors (3.3, R 1.5-7.8, n = 32; p = 0.01). In rHGG, a trend toward higher SUVmax values in grade IV tumors was observed (p = 0.13). Median MRIvol was 32.34 (R 8.75-108.77) cm3 in pGBM (n = 16) and 20.77 (R 0.63-128.44) cm3 in rHGG patients (n = 27). The highest median CI was observed for 40% (pGBM, 0.31) and 50% (rHGG, 0.43, all tumors) isodose, with 70% (40%) isodose in grade III (IV) rHGG tumors (median CI, 0.38 and 0.49). High SUVmax was linked to shorter survival in pGBM (>3.3, p = 0.001, OR 6.0 [2.1-17.4]) and rHGG (>2.8, p = 0.02, OR 4.1 [1.2-13.9]). SUVmax showed associations with inferred monocyte fractions, hypoxia, and TGFbeta pathway activity and links to immune checkpoint gene expression from WBT lbx.
UNASSIGNED: The benefits of 18F-FET-PET imaging on gross tumor volume (GTV) definition for particle radiotherapy warrant further evaluation. SUVmax might assist in prognostic stratification of HGG patients for particle radiotherapy, highlights heterogeneity in rHGG, and is positively associated with unfavorable signatures in peripheral whole-blood transcriptomes.